Published in Cancer Res on August 01, 2001
Large effects from small exposures. I. Mechanisms for endocrine-disrupting chemicals with estrogenic activity. Environ Health Perspect (2003) 4.19
Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cells. Br J Cancer (2006) 1.49
Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions. Endocr Rev (2008) 1.38
The IGF pathway regulates ERα through a S6K1-dependent mechanism in breast cancer cells. Mol Endocrinol (2011) 1.27
Estrogen receptor-alpha hinge-region lysines 302 and 303 regulate receptor degradation by the proteasome. Mol Endocrinol (2008) 1.14
Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial. J Natl Cancer Inst (2012) 1.13
p38gamma mitogen-activated protein kinase integrates signaling crosstalk between Ras and estrogen receptor to increase breast cancer invasion. Cancer Res (2006) 1.09
Functional activation of the estrogen receptor-α and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole. Cancer Res (2011) 1.09
Insulin receptor substrates (IRSs) and breast tumorigenesis. J Mammary Gland Biol Neoplasia (2008) 1.07
Dietary isoflavones differentially induce gene expression changes in lymphocytes from postmenopausal women who form equol as compared with those who do not. J Nutr Biochem (2006) 1.04
Long-range transcriptional control of progesterone receptor gene expression. Mol Endocrinol (2009) 1.03
Insulin-like growth factor-I receptor (IGF-IR) translocates to nucleus and autoregulates IGF-IR gene expression in breast cancer cells. J Biol Chem (2011) 1.03
Epigenetic regulation in estrogen receptor positive breast cancer--role in treatment response. J Mammary Gland Biol Neoplasia (2010) 1.02
The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer. Breast Cancer Res (2008) 1.01
Proteasome inhibition represses ERalpha gene expression in ER+ cells: a new link between proteasome activity and estrogen signaling in breast cancer. Oncogene (2009) 0.96
Estrogen-mediated downregulation of CD24 in breast cancer cells. Int J Cancer (2008) 0.95
Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer. Sci Transl Med (2014) 0.94
Nuclear IRS-1 and cancer. J Cell Physiol (2012) 0.94
The R-Ras GTPase mediates cross talk between estrogen and insulin signaling in breast cancer cells. Mol Cell Biol (2006) 0.86
RAC3 is a pro-migratory co-activator of ERα. Oncogene (2011) 0.86
Putative biomarkers and targets of estrogen receptor negative human breast cancer. Int J Mol Sci (2011) 0.85
Cdc42 overexpression induces hyperbranching in the developing mammary gland by enhancing cell migration. Breast Cancer Res (2013) 0.85
High-content screening and mechanism-based evaluation of estrogenic botanical extracts. Comb Chem High Throughput Screen (2008) 0.85
Identification of Insulin-Like Growth Factor-I Receptor (IGF-IR) Gene Promoter-Binding Proteins in Estrogen Receptor (ER)-Positive and ER-Depleted Breast Cancer Cells. Cancers (Basel) (2010) 0.84
Genomic responses from the estrogen-responsive element-dependent signaling pathway mediated by estrogen receptor alpha are required to elicit cellular alterations. J Biol Chem (2009) 0.84
Serum and glucocorticoid-regulated kinase 1 (SGK1) activation in breast cancer: requirement for mTORC1 activity associates with ER-alpha expression. Breast Cancer Res Treat (2012) 0.83
Histone H1 phosphorylation in breast cancer. J Proteome Res (2014) 0.83
Genistein as a Potential Anticancer Agent against Ovarian Cancer. J Tradit Complement Med (2012) 0.83
The impact of IGF-1R expression on the outcomes of patients with breast cancer: a meta-analysis. Onco Targets Ther (2015) 0.83
Progesterone receptor-B regulation of insulin-like growth factor-stimulated cell migration in breast cancer cells via insulin receptor substrate-2. Mol Cancer Res (2008) 0.82
Fulvestrant regulates epidermal growth factor (EGF) family ligands to activate EGF receptor (EGFR) signaling in breast cancer cells. Breast Cancer Res Treat (2013) 0.81
Mapping ERβ genomic binding sites reveals unique genomic features and identifies EBF1 as an ERβ interactor. PLoS One (2013) 0.80
CD24 cross-linking induces apoptosis in, and inhibits migration of, MCF-7 breast cancer cells. BMC Cancer (2008) 0.79
Plant sterols as anticancer nutrients: evidence for their role in breast cancer. Nutrients (2013) 0.78
Clinical instability of breast cancer markers is reflected in long-term in vitro estrogen deprivation studies. BMC Cancer (2013) 0.78
A Role for Histone H2B Variants in Endocrine-Resistant Breast Cancer. Horm Cancer (2015) 0.77
How does the estrogen receptor work? Breast Cancer Res (2002) 0.76
Insulin-like Growth Factor 1 Signaling Axis Meets p53 Genome Protection Pathways. Front Oncol (2016) 0.75
Nucleophosmin/B23 is a negative regulator of estrogen receptor α expression via AP2γ in endometrial cancer cells. Oncotarget (2016) 0.75
Dynamin II is required for 17β-estradiol signaling and autophagy-based ERα degradation. Sci Rep (2016) 0.75
Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell (1995) 12.39
Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med (2001) 12.38
Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol (1999) 11.18
p53-independent expression of p21Cip1 in muscle and other terminally differentiating cells. Science (1995) 6.01
Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. Proc Natl Acad Sci U S A (1997) 5.44
Abnormal morphogenesis but intact IKK activation in mice lacking the IKKalpha subunit of IkappaB kinase. Science (1999) 5.15
p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev (1995) 4.87
Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet (2001) 4.79
Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood (1997) 4.78
Relative binding affinity-serum modified access (RBA-SMA) assay predicts the relative in vivo bioactivity of the xenoestrogens bisphenol A and octylphenol. Environ Health Perspect (1997) 4.62
Interleukin-17 and lung host defense against Klebsiella pneumoniae infection. Am J Respir Cell Mol Biol (2001) 4.56
Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell (1995) 4.48
Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst (1993) 4.45
Activation of Arp2/3 complex-mediated actin polymerization by cortactin. Nat Cell Biol (2001) 4.38
Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst (1994) 4.28
Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. Mol Cell Biol (2001) 4.09
Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1alpha. J Clin Invest (1999) 4.00
Vertebrate Sprouty genes are induced by FGF signaling and can cause chondrodysplasia when overexpressed. Development (1999) 3.84
Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet (2000) 3.67
Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat (1992) 3.63
Prostate enlargement in mice due to fetal exposure to low doses of estradiol or diethylstilbestrol and opposite effects at high doses. Proc Natl Acad Sci U S A (1997) 3.61
Aberrant subcellular localization of BRCA1 in breast cancer. Science (1995) 3.61
Rapid exchange of histone H1.1 on chromatin in living human cells. Nature (2000) 3.59
Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood (1997) 3.56
p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature (1999) 3.55
A human RNA polymerase II complex containing factors that modify chromatin structure. Mol Cell Biol (1998) 3.45
The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer (1980) 3.34
The impact of clean indoor-air laws and cigarette smuggling on demand for cigarettes: an empirical model. Health Econ (2000) 3.31
CCAAT/enhancer binding protein alpha is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors. Mol Cell Biol (1998) 3.19
A physiologically based approach to the study of bisphenol A and other estrogenic chemicals on the size of reproductive organs, daily sperm production, and behavior. Toxicol Ind Health (1998) 3.18
A pre-mRNA-binding protein accompanies the RNA from the gene through the nuclear pores and into polysomes. Cell (1996) 2.94
Dedifferentiation of epidermal cells to stem cells in vivo. Lancet (2001) 2.90
Multiple functional domains of human transcription factor IIB: distinct interactions with two general transcription factors and RNA polymerase II. Genes Dev (1993) 2.87
At least one intron is required for the nonsense-mediated decay of triosephosphate isomerase mRNA: a possible link between nuclear splicing and cytoplasmic translation. Mol Cell Biol (1998) 2.79
Nucleotide sequence, transcription map, and mutation analysis of the 13q14 chromosomal region deleted in B-cell chronic lymphocytic leukemia. Blood (2001) 2.73
Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene. Nat Genet (1997) 2.64
An evidence ontology for use in pathway/genome databases. Pac Symp Biocomput (2004) 2.63
The early prediction of mortality in acute pancreatitis: a large population-based study. Gut (2008) 2.59
Statistical analysis of array expression data as applied to the problem of tamoxifen resistance. J Natl Cancer Inst (1999) 2.58
Modular nature of abscisic acid (ABA) response complexes: composite promoter units that are necessary and sufficient for ABA induction of gene expression in barley. Plant Cell (1996) 2.56
Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci U S A (1998) 2.55
Borrelia burgdorferi strain 25015: characterization of outer surface protein A and vaccination against infection. J Immunol (1992) 2.49
Fgf8 signalling from the AER is essential for normal limb development. Nat Genet (2000) 2.44
The three-dimensional structure of a glutathione S-transferase from the mu gene class. Structural analysis of the binary complex of isoenzyme 3-3 and glutathione at 2.2-A resolution. Biochemistry (1992) 2.43
Conjugation of biomolecules with luminophore-doped silica nanoparticles for photostable biomarkers. Anal Chem (2001) 2.42
A universal nucleoside for use at ambiguous sites in DNA primers. Nature (1994) 2.38
In vitro and in vivo regulation of antioxidant response element-dependent gene expression by estrogens. Endocrinology (2003) 2.35
Epidemiological link between exposure to poultry and all influenza A(H7N9) confirmed cases in Huzhou city, China, March to May 2013. Euro Surveill (2013) 2.34
Nuclear localization of unoccupied oestrogen receptors. Nature (1984) 2.33
Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol (1999) 2.32
Induction of terminal differentiation by constitutive activation of p38 MAP kinase in human rhabdomyosarcoma cells. Genes Dev (2000) 2.21
Cholesterol modulates membrane traffic along the endocytic pathway in sphingolipid-storage diseases. Nat Cell Biol (1999) 2.16
Estimating the number of people at risk for and living with HIV in China in 2005: methods and results. Sex Transm Infect (2006) 2.15
Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res (1985) 2.13
Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol (1987) 2.12
Forkhead homologue in rhabdomyosarcoma functions as a bifunctional nuclear receptor-interacting protein with both coactivator and corepressor functions. J Biol Chem (2001) 2.07
Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst (1998) 2.06
ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen. Cancer (2000) 2.05
Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol (1992) 2.05
Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol (1999) 2.00
Altered prostate growth and daily sperm production in male mice exposed prenatally to subclinical doses of 17alpha-ethinyl oestradiol. Hum Reprod (2001) 2.00
Injecting drug use and HIV infection in southwest China. AIDS (1994) 1.91
Significance of axillary lymph node metastasis in primary breast cancer. J Clin Oncol (1999) 1.89
Evolution of beta-cell dysfunction in the male Zucker diabetic fatty rat. Diabetes (1995) 1.87
The SH2 domain protein GRB-7 is co-amplified, overexpressed and in a tight complex with HER2 in breast cancer. EMBO J (1994) 1.87
Risk factors for acute hepatitis B and its progression to chronic hepatitis in Shanghai, China. Gut (2008) 1.86
Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat (1998) 1.85
Enrichment of cis-regulatory gene expression SNPs and methylation quantitative trait loci among bipolar disorder susceptibility variants. Mol Psychiatry (2012) 1.84
A combinatorial approach to materials discovery. Science (1995) 1.84
Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol (1984) 1.84
Analyses of volatile organic compounds from human skin. Br J Dermatol (2008) 1.82
Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. Am J Pathol (1995) 1.81
Brain ischemia and reperfusion activates the eukaryotic initiation factor 2alpha kinase, PERK. J Neurochem (2001) 1.81
Absence of a holelike fermi surface for the iron-based K0.8F1.7Se2 superconductor revealed by angle-resolved photoemission spectroscopy. Phys Rev Lett (2011) 1.81
The mitochondrial KATP channel as a receptor for potassium channel openers. J Biol Chem (1996) 1.77
PU.1 (Spi-1) autoregulates its expression in myeloid cells. Oncogene (1995) 1.76
Congenital muscular dystrophy with rigid spine syndrome: a clinical, pathological, radiological, and genetic study. Ann Neurol (2000) 1.75
Molecular basis for specific recognition of both RNA and DNA by a zinc finger protein. Science (1993) 1.75
Loss of heterozygosity at D14S62 and metastatic potential of breast cancer. J Natl Cancer Inst (1999) 1.75
Structure and regulation of amiloride-sensitive sodium channels. Annu Rev Physiol (2000) 1.74
Some capabilities for model-based and model-free linkage analysis using the program package S.A.G.E. (Statistical Analysis for Genetic Epidemiology). Hum Hered (2011) 1.73
Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study. N Engl J Med (1989) 1.70
Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetes-related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia (2010) 1.68
Evaluation of definitions for sepsis. Chest (1992) 1.68
Cloning and gene mapping of the chromosome 13q14 region deleted in chronic lymphocytic leukemia. Genomics (1997) 1.68
Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. J Clin Oncol (1994) 1.67
Antibody to caspase-cleaved actin detects apoptosis in differentiated neuroblastoma and plaque-associated neurons and microglia in Alzheimer's disease. Am J Pathol (1998) 1.67
Odorant receptors on axon termini in the brain. Science (2004) 1.67
Crosstalk between the insulin-like growth factors and estrogens in breast cancer. J Mammary Gland Biol Neoplasia (2000) 1.66
Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Womens Health Gend Based Med (2001) 1.65
Biochemically functionalized silica nanoparticles. Analyst (2001) 1.64
Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients. Oncogene (2009) 1.64
Wheat genetic diversity trends during domestication and breeding. Theor Appl Genet (2005) 1.63
Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen. J Clin Oncol (2005) 1.63
Regulated processing of hepatitis C virus core protein is linked to subcellular localization. J Virol (1997) 1.63
Loss of mucosal CD103+ DCs and IL-17+ and IL-22+ lymphocytes is associated with mucosal damage in SIV infection. Mucosal Immunol (2012) 1.62